protein

Recombinant Human Apolipoprotein A-V

MBS145975

0.002 mg

140 USD

Recombinant Protein

Recombinant Human Apolipoprotein A-V

[Apolipoprotein A-V]

[APOA5 Human; Apolipoprotein A-V Human Recombinant; Apolipoprotein A-V; Apo-AV; ApoA-V; Apolipoprotein A5; Regeneration-associated protein 3; APOA5; RAP3; APOAV]

[apolipoprotein A-V; Apolipoprotein A-V; apolipoprotein A-V; apo-AV; apolipoprotein A5; regeneration-associated protein 3; apolipoprotein A-V; Apolipoprotein A5; Regeneration-associated protein 3]

[APOA5]

[APOA5; APOA5; RAP3; APOAV; RAP3; Apo-AV; ApoA-V]

APOA5_HUMAN

Escherichia coli

366

MGSSHHHHHH SSGLVPRGSH MGS RKGFWDY FSQTSGDKGR VEQIHQQKMA REPATLKDSL EQDLNNMNKF LEKLRPLSGS EAPRLPQDPV GMRRQLQEEL EEVKARLQPY MAEAHELVGW NLEGLRQQLK PYTMDLMEQV ALRVQELQEQ LRVVGEDTKA QLLGGVDEAW ALLQGLQSRV VHHTGRFKEL FHPYAESLVS GIGRHVQELH RSVAPHAPAS PARLSRCVQV LSRKLTLKAK ALHARIQQNL DQLREELSRA FAGTGTEEGA GPDPQMLSEE VRQRLQAFRQ DTYLQIAAFT RAIDQETEEV QQQLAPPPPG HSAFAPEFQQ TDSGKVLSKL QARLDDLWED ITHSLHDQGH SHLGDP.

Greater than 85.0% as determined by SDS-PAGE.

APOA5 protein solution (0.25mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 10% glycerol and 0.4M Urea.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Physical Appearance: Sterile filtered colorless solution.

CYTOKINES AND GROWTH FACTORS; Cytokines; Apolipoprotein

Description: APOA5 Human Recombinant produced in E Coli is a single, non-glycosylated polypeptide chain containing 366 amino acids (24-366 a.a.) and having a molecular mass of 41.3kDa. APOA5 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. Introduction: ApoA5 is an important regulator of serum triglyceride concentrations. An ApoA5 mouse nock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. Furthermore, peroxisome proliferators-activated receptoragonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. There is very little known about ApoA5 protein in human serum. Lately, it was established that ApoA5 is present in the human serum and it can be detected by polyclonal antibodies against both the HN2 and COOH termini, but at much lower concentration than other apolipoproteins.

262231737

NP_001160070.1

NM_001166598.1

Q6Q788

Chylomicron-mediated Lipid Transport Pathway (106157); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Pathway (477135); Metabolism Of Lipids And Lipoproteins Pathway (160976); PPAR Signaling Pathway (83042); PPAR Signaling Pathway (450); PPARA Activates Gene Expression Pathway (530749); Regulation Of Lipid Metabolism By Peroxisome Proliferator-activated Receptor Alpha (PPARalpha) Pathway (119544)

The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Oct 2009]

APOA5: Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Interacts with GPIHBP1. Up-regulated by PPARA agonists, which are used clinically to lower serum TG (such as fibrates). Liver and plasma. Belongs to the apolipoprotein A1/A4/E family. Protein type: Secreted, signal peptide; Secreted; Lipid-binding. Chromosomal Location of Human Ortholog: 11q23. Cellular Component: extracellular space; chylomicron; extracellular region. Molecular Function: heparin binding; enzyme binding; low-density lipoprotein receptor binding; cholesterol transporter activity; enzyme activator activity; cholesterol binding; phospholipid binding; phosphatidylcholine binding; lipid binding. Biological Process: positive regulation of fatty acid biosynthetic process; organ regeneration; response to hormone stimulus; neurite regeneration; positive regulation of lipid catabolic process; lipoprotein metabolic process; cholesterol efflux; cellular lipid metabolic process; lipid transport; cholesterol biosynthetic process; positive regulation of receptor-mediated endocytosis; phosphatidylcholine metabolic process; cholesterol homeostasis; triacylglycerol metabolic process; reverse cholesterol transport; phospholipid efflux; regulation of cholesterol absorption; tissue regeneration; acylglycerol homeostasis; triacylglycerol catabolic process; positive regulation of lipoprotein lipase activity. Disease: Hypertriglyceridemia, Familial; Hyperlipoproteinemia, Type V

0.002 mg

140 USD

0.01 mg

205

1 mg

5015